US1101221083 - BMY - 850501 (XNYS)
BRISTOL-MYERS SQUIBB CO Aktie
49,96 USD
Aktuelle Kurse von BRISTOL-MYERS SQUIBB CO
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NYSE |
BMY
|
USD
|
19.09.2024 01:54
|
49,96 USD
| 49,49 USD | 0,95 % |
XETRA |
BRM.DE
|
EUR
|
18.09.2024 17:35
|
44,57 EUR
| 44,59 EUR | -0,03 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 3,65 % | 1,21 % | 22,45 % | -3,51 % | -14,48 % | -0,55 % |
Firmenprofil zu BRISTOL-MYERS SQUIBB CO Aktie
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Investierte Fonds
Folgende Fonds haben in BRISTOL-MYERS SQUIBB CO investiert:
Fonds | Vol. in Mio 34.308,76 | Anteil (%) 2,38 % |
Fonds | Vol. in Mio 6.889,62 | Anteil (%) 1,89 % |
Fonds | Vol. in Mio 2.069,92 | Anteil (%) 1,68 % |
Fonds | Vol. in Mio 598,56 | Anteil (%) 1,26 % |
Fonds | Vol. in Mio 2.556,87 | Anteil (%) 0,98 % |
Unternehmensdaten zur BRISTOL-MYERS SQUIBB CO Aktie
Name BRISTOL-MYERS SQUIBB CO
Firma Bristol-Myers Squibb Company
Symbol BMY
Website https://www.bms.com
Heimatbörse
NYSE
WKN 850501
ISIN US1101221083
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - General
CEO Dr. Christopher S. Boerner Ph.D.
Marktkapitalisierung 99 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 34,1 T
Adresse 430 East 29th Street, 10016 New York
IPO Datum 1972-06-01
Dividenden von BRISTOL-MYERS SQUIBB CO
Ex-Datum | Dividende pro Aktie |
---|---|
05.07.2024 | 0,60 USD |
04.04.2024 | 0,60 USD |
04.01.2024 | 0,60 USD |
05.10.2023 | 0,57 USD |
06.07.2023 | 0,57 USD |
06.04.2023 | 0,57 USD |
05.01.2023 | 0,57 USD |
06.10.2022 | 0,54 USD |
30.06.2022 | 0,54 USD |
31.03.2022 | 0,54 USD |
Aktien-Splits
Datum | Split |
---|---|
07.08.2001 | 1000000:951777 |
01.03.1999 | 2:1 |
03.03.1997 | 2:1 |
10.06.1987 | 2:1 |
27.05.1983 | 2:1 |
31.05.1977 | 2:1 |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | BRM.F |
NYSE | BMY |
XETRA | BRM.DE |
Weitere Aktien
Investoren die BRISTOL-MYERS SQUIBB CO halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024